CClinicalTrials.gg
CompletedNCT04024098Updated Oct 14, 2020

An Epidemiological Survey of Cancer-related Fatigue Among Taiwanese Gynecologic Cancer Patients

An observational study in Fatigue, sponsored by Chang Gung Memorial Hospital. Completed at 1 site in Taiwan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.

Sponsored by Chang Gung Memorial Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
200
Ages
20 Years and older
Sex
Female
01

Study summary

This study aim is to examine the prevalence, severity, and management of CRF among Taiwanese gynecologic cancer patients.

Read the detailed description

The cross-sectional survey is conducted at oncology inpatients unit and outpatients clinics of hospitals in Taiwan. Furthermore, the results will elucidate not only the epidemiology of CRF in Taiwan, but will supply physicians with more understanding about CRF, and help them to enhance the quality on cancer care to being perfected in the future.

02

Conditions studied

  • Fatigue

Browse trials for

03

In context

Fatigue

1,860 studies on the registry are indexed under Fatigue; 376 are open to participants now.

This study's enrollment of 200 is above the median of 100 across 367 observational studies indexed under Fatigue.

Browse Fatigue studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,064 studies on the registry; 235 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

gynecologic cancer patients

Inclusion criteria

  • Patients who signed the informed consent form
  • The age of eligible patients should be ≥ 20 years old.
  • Inpatients or outpatients who have been given a diagnosis of gynecologic cancer.
  • Able to communicate verbally and completely fill out the questionnaires

Exclusion criteria

Exclusion Criteria:

  • Patients who have been given a diagnosis of cognitive impairment are unable to complete the questionnaires
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
200 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Cancer-related fatigue evaluation-1

    ICD-10 Fatigue Criteria

    Time frame: 10 minuts

  2. Cancer-related fatigue evaluation-2

    Brief Fatigue Inventory-Taiwan Form (BFI-T)

    Time frame: 8 minuts

  3. Symptoms and Quality of Life Assessments-1

    Functional Assessment of Cancer Therapy-General quality of life questionnaire (FACT-G7)

    Time frame: 4 minuts

  4. Symptoms and Quality of Life Assessments-2

    cancer symptom survey (self-designed questionnaire)

    Time frame: 5 minuts

07

Study locations

1 site
  • Kaohsiung Chan Gung Memorial Hospital
    Kaohsiung, Taiwan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04024098
Lead sponsor
Chang Gung Memorial Hospital
Responsible party
CHING-CHOU TSAI (Attending physician, Chang Gung Memorial Hospital) — Principal investigator
First posted
Jul 18, 2019
Start date
Jul 11, 2019
Primary completion
Aug 31, 2020
Completion
Aug 31, 2020
Last update
Oct 14, 2020

Study contacts

CHING-CHOU TSAI, Dr.
principal investigator · Kaohsiung Chan Gung Memorial Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion